Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04462471
Title Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST